{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"303.9","value":"9.33"}]}],"title":"C Reactive Protein: Fold-change from BL Grade 4 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"164.6","value":"36.62"}]}],"title":"Ferritin: Fold-change from BL Grade 4 CRS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Profile of soluble immune factors of key inflammatory markers and cytokine parameters in blood by maximum CRS grade that may be key to cytokine release syndrome (CRS).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Safety Set: The Safety set comprised all patients who received tisagenlecleucel infusion with evaluable data. This analysis included a subset of Safety set who had any data of the particular biomarker at the specific timepoint. Therefore, no participants in Cohort 1 had biomarker data at this time point, so no data was collected for Cohort 1.","reportingStatus":"POSTED","timeFrame":"Maximum post-baseline (approx. 60 months)","title":"Frequent Monitoring of Concentrations of Soluble Immune Factors in Blood (C Reactive Protein & Ferritin)","type":"SECONDARY","unitOfMeasure":"fold-change from baseline"}